Rebecca Byam - 19 Jul 2021 Form 3 Insider Report for HCW Biologics Inc. (HCWB)

Role
Chief Financial Officer
Signature
/s/ Hing C. Wong, as Attorney-in-Fact for Rebecca A. Byam
Issuer symbol
HCWB
Transactions as of
19 Jul 2021
Net transactions value
$0
Form type
3
Filing time
19 Jul 2021, 16:54:43 UTC
Next filing
23 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding HCWB Common Stock 27,000 19 Jul 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HCWB Stock Option (Right to Buy) 19 Jul 2021 Common Stock 107,999 $0.1400 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These option shares were part of a stock option grant covering 135,000 shares of common stock. 20% of the total shares subject to the stock option grant vested on October 10, 2020; 20% of the total shares subject to the stock option grant will vest on October 10, 2021; 25% of the total shares subject to the stock option grant will vest on October 10, 2022; and 35% of the total shares subject to the stock option grant will vest on October 10, 2023, subject to her continuous service through the applicable vesting date. The option is subject to additional vesting acceleration pursuant to her Employment Agreement.

Remarks:

Exhibit 24.1: Power of Attorney